检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:汤文英[1] 汤钊猷[1] 刘康达[1] 邹合强[1] 鲍卫华[1]
机构地区:[1]上海医科大学肝癌研究所
出 处:《上海医科大学学报》1995年第2期135-137,共3页Journal of Fudan University(Medical Science)
基 金:中山医院中青年研究基金资助
摘 要:用ABC免疫组织化学方法(简称组化)对92例肝细胞肝癌(HCC)标本进行了耐 药基因产物 P-GP的检测。结果:术前未治疗的 76例 HCC中,癌与癌周肝 P-GP组化染色 阳性率分别为60.5%(46/76)与69.7%(53/76);由导向综合治疗后切除的16例标本中其癌 与癌周肝分别为31.2%(5/16)与78.3%(11/15)。表明经导向综合治疗后HCC中P-GP的 表达显著低于来治疗组(P<0.05)。提示导向综合治疗有助于克服HCC耐药。A total of 96 specimens of hepatocellular carcinoma (HCC) and its surrounding liver tissues were studied to assess the expression multidrug resistance (mdr) gene product P-glycoprotein (P-GP) in HCC. P-GP was evaluated by an immunopexoxidase detection system. Results: In 76 untreated cases, P-GP was detected in 60.5%(46/76) of HCC, and in 69.7%(53/76) of surrounding liver tissues. In multimodality targeting treatment group (n= 16), expression of P-GP was observed in only 31.2%(5/16) of HCC and in 73.3%(11/15) of surrounding liver tissues. Expresaion of P-CP in multimodality targeting treatment group statistically lower then thet of untreated group (P<0.05). The results indicate that by multimodality targeting treatment, such as radioimmunotherapy, might change multidrug resistance of HCC.
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.229